Regeneron Receives Resounding “No” From Advisory Committee On Arcalyst Approval In Gout
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee votes 11-0 against approval of the interleukin-1 blocker for prevention of gout flares during uric-acid lowering therapy, saying the wrong population was studied and more data is needed.